A possible role of allelic variation on chromosome 19q13 in multiple sclerosis (MS) susceptibility has been suggested. We tested association of sixteen 19q13 markers with MS in 459 families. Nominally significant associations were tested in an independent set of 323 families as well as in the pooled set of 782 families. We were not able to confirm previously suggested associations with APOE, GIPR, ZNF45, ILT6 and D19S585. In the screening dataset nominally significant associations were found with D19S867 and with APOE haplotype (p = 0.007 in both), but these were not replicated in the independent dataset nor in the pooled analysis of 757 families. Thus, we were not able to detect any statistically significant allelic associations. Re-sequencing based approaches may be required for elucidating the role chromosome 19q13 with MS.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system resulting in demyelination and axonal damage (Compston and Coles, 2002) . Its etiology is still unclear, but both genetic and environmental factors have been shown to be involved. Multiple genes, still mostly unknown, are likely to modify disease susceptibility. The most consistent genetic finding thus far is the association between MS and the HLA-DR15,DQ6 haplotype (Olerup and Hillert, 1991; Lincoln et al., 2005; Hafler et al., 2007) . Other loci have been more difficult to detect, but recently associations with a small number of genes have been replicated in more than one population, such as protein kinase C alpha (PRKCA) (Barton et al., 2004; Saarela et al., 2006) , IRF5 (Kristjansdottir et al., 2008) , EVI5 (Hafler et al., 2007; Hoppenbrouwers et al., 2008) , the interleukin 2 and 7 receptor alpha chain genes respectively (IL2RA and IL7RA) (Zhang et al., 2005; Gregory et al., 2007; Hafler et al., 2007) .
Chromosome 19q13 is one of the genomic regions that reportedly exhibits clustering of predisposing loci in several putative autoimmune diseases (Becker et al., 1998) . In systemic lupus erythematosus 19q13 has been suggested, based on linkage studies, as a susceptibility locus in European Americans (Xing et al., 2007) . In MS the situation is presently ambiguous. There are several reports providing weak evidence for an MS susceptibility gene on 19q13, but there is lack of replication (especially in allelic associations), and the signals have been scattered in distinct subregions of 19q13. A metaanalysis of linkage screens identified 19q13 as one of the most interesting non-HLA loci (Wise et al., 1999) . In our previous study in Finnish multiplex families we obtained weak linkage evidence for the 19q13.1 subregion (Reunanen et al., 2002) . Here we have performed a larger follow-up study to test, via allelic association, whether we are able to obtain evidence for an MS susceptibility locus in 19q13. Journal of Neuroimmunology 208 (2009) 119-124 
